| 1. |
- Almjashev, V.I., et al.
(författare)
-
Phase equilibria in the FeO(1+x)-UO(2)-ZrO(2) system in the FeO(1+x)-enriched domain
- 2010
-
Ingår i: Journal of Nuclear Materials. - : Elsevier BV. - 0022-3115 .- 1873-4820. ; 400:2, s. 119-126
-
Tidskriftsartikel (refereegranskat)abstract
- Experimental results of the investigation of the FeO(1+x)UO(2)-ZrO(2) system in neutral atmosphere are presented. The ternary eutectic position and the composition of the phases crystallized at this point have been determined. The phase diagram is constructed for the FeO(1+x)-enriched region and the onset melting temperature of 1310 degrees C probably represents a local minimum and so will be a determining factor in this system and its application to safety studies in nuclear reactors.
|
|
| 2. |
- Almjashev, V.I., et al.
(författare)
-
Ternary eutectics in the systems FeO-UO2-ZrO2 and Fe2O3-U3O8-ZrO21
- 2011
-
Ingår i: Radiochemistry. - 1066-3622. ; 53:1, s. 13-18
-
Tidskriftsartikel (refereegranskat)abstract
- The systems FeO–UO2–ZrO2 (in inert atmosphere) and Fe2O3–U3O8–ZrO2 (in air) were studied. Forthe FeO–UO2–ZrO2 system, the eutectic temperature was found to be 1310°С, with the following componentconcentrations (mol %): 91.8 FeO, 3.8 UO2, and 4.4 ZrO2. For the Fe2O3–U3O8–ZrO2 system, the eutectictemperature was found to be 1323°С, with the following component concentrations (mol %): 67.4 FeO1.5,30.5 UO2.67, and 2.1 ZrO2. The solubility limits of iron oxides in the phases based on UO2(ZrO2,FeO) andUO2.67(ZrO2,FeO1.5) were determined
|
|
| 3. |
- Delgado-Lista, J., et al.
(författare)
-
A gene variation (rs12691) in the CCAT/enhancer binding protein alpha modulates glucose metabolism in metabolic syndrome
- 2013
-
Ingår i: NMCD. Nutrition Metabolism and Cardiovascular Diseases. - : Elsevier BV. - 0939-4753 .- 1590-3729. ; 23:5, s. 417-423
-
Tidskriftsartikel (refereegranskat)abstract
- Background and aims: CCAAT/enhancer-binding protein alpha (CEBPA) is a transcription factor involved in adipogenesis and energy homeostasis. Caloric restriction reduces CEBPA protein expression in patients with metabolic syndrome (MetS). A previous report linked rs12691 SNP in CEBPA to altered concentration of fasting triglycerides. Our objective was to assess the effects of rs12691 in glucose metabolism in Metabolic Syndrome (MetS) patients. Methods and results: Glucose metabolism was assessed by static (glucose, insulin, adiponectin, leptin and resistin plasma concentrations) and dynamic (disposition index, insulin sensitivity index, HOMA-IR and acute insulin response to glucose) indices, performed at baseline and after 12 weeks of 4 dietary interventions (high saturated fatty acid (SFA), high monounsaturated fatty acid (MUFA), low-fat and low-fat-high-n3 polyunsaturated fatty acid (PUFA)) in 486 subjects with MetS. Carriers of the minor A allele of rs12691 had altered disposition index (p = 0.0003), lower acute insulin response (p = 0.005) and a lower insulin sensitivity index (p = 0.025) indicating a lower insulin sensitivity and a lower insulin secretion, at baseline and at the end of the diets. Furthermore, A allele carriers displayed lower HDL concentration. Conclusion: The presence of the A allele of rs12691 influences glucose metabolism of MetS patients. Clinical Trials Registry number NCT00429195.
|
|
| 4. |
- Delgado-Lista, J., et al.
(författare)
-
Pleiotropic effects of TCF7L2 gene variants and its modulation in the metabolic syndrome : From the LIPGENE study
- 2011
-
Ingår i: Atherosclerosis. - : Elsevier BV. - 0021-9150 .- 1879-1484. ; 214:1, s. 110-116
-
Tidskriftsartikel (refereegranskat)abstract
- Aims/hypothesis: Variants of the TCF7L2 gene predict the development of type 2 diabetes mellitus (T2DM). We investigated the associations between gene variants of TCF7L2 and clinical features of the metabolic syndrome (MetS) (an entity often preceeding T2DM), and their interaction with non-genetic factors, including plasma saturated fatty acids (SFA) concentration and insulin resistance (IR). Methods: Fasting lipid profiles, insulin sensitivity, insulin secretion, anthropometrics, blood pressure and 10 gene variations of the TCF7L2 gene were determined in 450 subjects with MetS. Results: Several single nucleotide polymorphisms (SNP) showed phenotypic associations independent of SFA or IR. Carriers of the rare T allele of rs7903146, and of three other SNPs in linkage disequilibrium with rs7903146, had lower blood pressure and insulin secretion. High IR and the presence of the T-allele of rs7903146 acted synergistically to define those with reduced insulin secretion. Carriers of the minor allele of rs290481 exhibited an altered lipid profile, with increased plasma levels of apolipoprotein B, non-esterified fatty acids, cholesterol and apolipoprotein B in triglyceride rich lipoproteins, and LDL cholesterol. Carriers of the minor allele of rs11196224 that had higher plasma SFA levels showed elevated procoagulant/proinflammatory biomarkers, impaired insulin secretion and increased IR, whereas carriers of the minor allele of rs17685538 with high plasma SFA levels exhibited higher blood pressure. Conclusions/interpretation: SNP in the TCF7L2 gene are associated with differences in insulin secretion, blood pressure, blood lipids and coagulation in MetS patients, and may be modulated by SFA in plasma or IR.
|
|
